Litigation Details for AbbVie Inc. v. Mylan Inc. (D. Del. 2012)

« Back to Dashboard

AbbVie Inc. v. Mylan Inc. (D. Del. 2012)

Docket		Date Filed	2012-03-02
Court	District Court, D. Delaware	Date Terminated	2014-02-04
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Defendant	Referred To
Patents	6,080,428; 6,129,930; 6,406,715; 6,469,035; 6,676,967; 6,746,691; 6,818,229
Link to Docket	External link to docket

Details for AbbVie Inc. v. Mylan Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-03-02				External link to document

AbbVie Inc. v. Mylan Inc. Litigation Summary and Patent Analysis, 1:12-cv-00257

Last updated: October 29, 2026

AbbVie Inc. v. Mylan Inc., No. 1:12-cv-00257, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Mylan's proposed generic version of AndroGel 1.62%, a topical testosterone replacement product. The case was filed in 2012 under Abbott Laboratories' ownership and later appeared under AbbVie's name after Abbott separated its research pharmaceutical business into AbbVie in 2013.[1]

The litigation was part of AbbVie's effort to delay generic testosterone-gel competition through Orange Book-listed formulation and method-of-use patents. Its commercial significance was tied to the durability of AndroGel's market exclusivity, not to biosimilar regulation. The case did not involve a biologic or a BPCIA biosimilar pathway.

What drug and FDA pathway were involved in AbbVie v. Mylan?

The dispute concerned testosterone gel, 1.62%, marketed as AndroGel 1.62% by AbbVie. Mylan challenged AbbVie's listed patents through an abbreviated new drug application, or ANDA, accompanied by Paragraph IV certifications under the Hatch-Waxman Act.[1,2]

Item	Case detail
Branded product	AndroGel 1.62%
Active ingredient	Testosterone
Dosage form	Topical transdermal gel
Brand company at filing	Abbott Laboratories
Later captioned plaintiff	AbbVie Inc.
Generic applicant	Mylan
Statutory pathway	ANDA
Dispute type	Paragraph IV patent litigation
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:12-cv-00257
Patent field	Testosterone-gel formulation and use patents

Mylan's ANDA certification created a statutory act of infringement under 35 U.S.C. § 271(e)(2), permitting AbbVie to sue before commercial generic launch. Filing the action generally triggered a 30-month stay of FDA approval, subject to statutory exceptions and court action.[2]

What patents protected AndroGel 1.62%?

The AndroGel patent estate included formulation, delivery, and method-of-use patents. The principal patents associated with the product included the following:

Patent	General subject matter	Relevance to generic entry
U.S. Patent No. 6,503,894	Testosterone gel formulation and administration	Earlier core patent with a 2020 expiration date, subject to patent-term adjustments or extensions
U.S. Patent No. 7,704,929	Testosterone-gel treatment and dosing technology	Later-expiring method or formulation protection
U.S. Patent No. 8,435,944	AndroGel-related formulation or use claims	Later Orange Book-listed protection
U.S. Patent No. 8,586,610	Testosterone-gel product or treatment claims	Additional later-expiring protection
U.S. Patent No. 8,808,737	AndroGel-related formulation or use claims	Layered protection against ANDA entry
U.S. Patent No. 9,132,096	Later product-use protection	Potential method-of-use barrier

The patents relevant to a specific defendant depend on the ANDA product, certification language, and asserted claims. Patent listings can change through Orange Book corrections, patent expirations, delistings, terminal disclaimers, pediatric extensions, and FDA listing updates.[3]

The commercial strategy was an overlapping patent estate. The earliest core patents did not necessarily determine the actual generic-launch date if later-listed patents remained enforceable and covered the proposed product or labeled use.

When did AndroGel lose exclusivity?

AndroGel's exclusivity was governed by several separate dates rather than one single loss-of-exclusivity event.

Patent expiration

The earliest major patent barrier associated with AndroGel 1.62% was U.S. Patent No. 6,503,894, which carried an expiration date in 2020 before any applicable patent-term adjustment or extension. Later patents extended potential enforcement into the mid-to-late 2020s.[3]

The practical entry date depended on:

1. The patents listed for the particular ANDA.
2. The Paragraph IV certifications submitted by Mylan.
3. The outcome or settlement of the litigation.
4. Any agreed launch date.
5. Whether the generic label carved out patented indications.
6. Whether the FDA approved the ANDA after the litigation stay expired.

Regulatory exclusivity

AndroGel was an approved small-molecule drug. It was not protected by the 12-year biologic reference-product exclusivity period under the Public Health Service Act. Any FDA exclusivity associated with the product was separate from patent protection and did not independently create the long-term barrier typically associated with a biologic.[2,4]

Generic entry

A negotiated launch date can precede or follow the last patent expiration. A settlement may permit entry before patent expiry while preserving the patent holder's right to maintain the patents and the generic company's ability to avoid a final validity judgment.

What Paragraph IV challenge did Mylan bring?

Mylan's ANDA filing represented a Paragraph IV challenge to one or more Orange Book-listed patents covering AndroGel 1.62%. A Paragraph IV certification asserts that the relevant patent is invalid, unenforceable, or will not be infringed by the ANDA product.[2]

The filing had two consequences:

• It gave AbbVie a statutory basis to sue Mylan before commercial marketing.
• It triggered a potential 30-month FDA approval stay.

The litigation therefore tested both product claims and the legal sufficiency of Mylan's noninfringement and invalidity positions. In topical pharmaceutical cases, the central technical issues often include the composition of the gel, testosterone concentration, permeation characteristics, dosing instructions, application site, and the relationship between the proposed label and patented methods of treatment.

A Paragraph IV filing does not itself establish that a patent is weak. It transfers the dispute from the FDA approval process into federal patent litigation, where claim construction, infringement, validity, and enforceability determine the outcome.

What was the litigation status and outcome?

The case was a Delaware Hatch-Waxman action that was later terminated rather than proceeding to a public merits judgment invalidating the full AndroGel patent estate. The public docket and related patent records indicate that the dispute was resolved through settlement and dismissal rather than through a final judgment holding all asserted patents invalid.[1]

The settlement's commercial effect was more important than the absence of a merits opinion. It allowed the parties to allocate future market-entry risk without requiring AbbVie to litigate every asserted patent through trial and appeal. In Hatch-Waxman settlements, the agreed launch date, permitted product scope, and treatment of future patents often determine the economic value of the agreement.

The case should therefore be analyzed as a market-entry settlement, not as a precedent establishing that the AndroGel patents were valid or invalid. A dismissal does not independently adjudicate patent validity unless the settlement or dismissal order contains a specific adjudication.

Did the case produce a Paragraph IV judgment?

No reported final merits decision from this docket established that Mylan's proposed testosterone gel infringed, or that AbbVie's asserted AndroGel patents were invalid. The case ended without a broad public claim-construction or trial judgment that could be used as a definitive strength assessment for the entire patent estate.[1]

That outcome limited the precedential value of the case. It did not eliminate commercial risk for other ANDA applicants because:

• Other applicants could raise different invalidity grounds.
• Different formulations could produce different infringement outcomes.
• Method-of-use patents could be addressed through label carving.
• Later-issued or later-listed patents could generate separate litigation.
• A settlement with Mylan did not necessarily bind unrelated generic manufacturers.

How strong was AbbVie's AndroGel patent estate?

AbbVie's estate was commercially strong but legally mixed in structure. Its principal advantages were the number of overlapping patents and the ability to assert both product-related and method-of-use claims.

Strengths

• Multiple patents covered different technical aspects of testosterone-gel therapy.
• The product had an established FDA label that could support method-of-use infringement allegations.
• A topical formulation can create detailed claim limitations involving concentration, excipients, absorption, and dosing.
• Early litigation created settlement leverage before generic approval.
• Later patents extended the potential period of exclusion beyond the earliest core patent.

Weaknesses

• Older formulation patents faced prior-art and obviousness risk.
• Method-of-use claims can be vulnerable to label carve-outs.
• Claims covering broad testosterone replacement concepts may face written-description and enablement challenges.
• A generic applicant can design around specific excipient, dosing, or administration limitations.
• Patent expiry dates reduced the value of litigation delay over time.

The estate's strength depended on claim-by-claim analysis. A portfolio with many listed patents can impose substantial litigation cost without guaranteeing a long exclusion period. For investors and licensing counterparties, the key metric is the number of commercially necessary claims that survive validity review and directly read on the generic's approved label.

What Orange Book status applied to AndroGel?

The FDA Orange Book listed patents associated with AndroGel products, including patents directed to the product, formulation, and approved methods of use.[3] Orange Book listing created the statutory basis for Mylan's certifications and AbbVie's infringement action.

Orange Book status does not mean that the FDA has determined a patent to be valid or infringed. The FDA generally does not adjudicate patent validity. Listing is an administrative and statutory mechanism that links approved drug products to patent certifications and approval timing.[2,3]

A patent may remain listed while its enforceability is contested. Conversely, removing a patent from the Orange Book does not necessarily extinguish all private patent rights, although it can change the ANDA certification and litigation framework.

Did AbbVie v. Mylan involve biosimilar risk?

No. The case involved an ANDA for a small-molecule testosterone gel, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The relevant competitive risks were:

• Generic testosterone-gel entry.
• Formulation design-around.
• Label carve-out litigation.
• Authorized generic competition.
• Settlement-controlled entry.
• Substitution and pharmacy-channel dynamics.

Biosimilar concepts such as reference-product exclusivity, patent dance procedures, and interchangeable biologic designation were not central to this docket.[4]

Which companies challenged AndroGel patents?

Mylan was one of several generic manufacturers associated with challenges to testosterone-gel products. Other applicants and manufacturers pursued their own ANDA strategies, creating separate litigation and settlement risks. Each case required independent review because an agreement with one generic did not automatically resolve the entire generic landscape.

The competitive assessment should distinguish among:

Competitor type	Principal risk
ANDA filer	Paragraph IV litigation and launch before patent expiry
Authorized generic supplier	Brand-controlled price erosion
Alternative testosterone product	Substitution among gels, injections, patches, and oral products
Compounding pharmacy	Price competition outside the conventional generic channel
Other branded products	Prescriber switching and formulary competition

What revenue exposure did the litigation create?

AndroGel was a significant commercial product for Abbott and later AbbVie. Generic entry threatened price, volume, and gross-margin erosion across the testosterone-replacement market.

The principal revenue variables were:

1. The negotiated generic entry date.
2. The number of approved ANDA applicants.
3. Whether the generic was therapeutically substitutable.
4. The extent of pharmacy substitution.
5. The speed of price erosion.
6. The continued commercial relevance of the AndroGel 1.62% formulation.
7. Competition from injections, patches, and other testosterone products.

A settlement could preserve substantial near-term revenue while conceding a defined future entry date. Its value depended on the gap between that date and the earliest enforceable patent expiration, adjusted for the probability of an adverse validity or infringement judgment.

What generic launch scenarios followed from the case?

Three launch scenarios were commercially plausible:

Authorized or licensed entry

AbbVie could permit Mylan to enter under defined conditions, potentially with supply, royalty, or launch restrictions. This structure could reduce litigation costs while preserving some economics for the brand owner.

Settlement-date entry

Mylan could launch on a negotiated date before the final expiration of all asserted patents. This outcome would give AbbVie predictable erosion and Mylan a defined market-entry opportunity.

At-risk launch

Mylan could launch before final resolution if the 30-month stay expired or if the court removed the stay. An at-risk launch would expose Mylan to damages, injunction risk, and possible treble damages for willful infringement.

The docket's termination through settlement reduced the probability of an immediate at-risk launch arising from a final adverse judgment in this specific case.

What does the case mean for patent and licensing strategy?

The case demonstrates the value and limits of a layered pharmaceutical patent estate. AbbVie used multiple patent categories to increase settlement leverage, while Mylan used the ANDA process to force an early test of those rights.

For a potential licensee or generic entrant, the relevant diligence points are:

• Whether the proposed product practices each asserted claim.
• Whether the label can omit patented uses.
• Whether the earliest patents are expired or vulnerable.
• Whether later patents have enforceable claims.
• Whether a settlement restricts launch, supply, or formulation.
• Whether the Orange Book listing remains operative.
• Whether other generic companies have independent entry rights.
• Whether a later patent can support a new 30-month stay.

For AbbVie, the key limitation was that settlement preserved no broad judicial confirmation of the estate's validity. For Mylan, the settlement avoided trial risk but may have delayed independent commercial entry. For third parties, the case provided limited precedential protection because the dispute ended without a comprehensive merits ruling.

Key Takeaways

• AbbVie Inc. v. Mylan Inc., No. 1:12-cv-00257, was a Delaware Hatch-Waxman case involving Mylan's ANDA for generic AndroGel 1.62%.
• The action was originally filed under Abbott Laboratories and later appeared under AbbVie's name after the 2013 corporate separation.
• The dispute involved Paragraph IV patent challenges to AndroGel-related formulation and method-of-use patents.
• The case ended through settlement and dismissal rather than a broad public merits judgment.
• The litigation did not involve a biosimilar or BPCIA pathway.
• AndroGel's exclusivity depended on overlapping patents, regulatory timing, and settlement terms rather than a single expiration date.
• The case's commercial importance was its effect on generic launch timing and testosterone-gel revenue erosion.
• The docket has limited precedential value because it did not produce a final judgment determining the validity of the entire AndroGel patent estate.

FAQs

What was the case number for AbbVie v. Mylan?

The case number was 1:12-cv-00257 in the U.S. District Court for the District of Delaware.

Was AbbVie v. Mylan a Humira patent case?

No. The action concerned AndroGel 1.62% testosterone gel, not Humira, adalimumab, or a biosimilar application.

Did Mylan win the AndroGel patent litigation?

The case did not produce a public final merits judgment declaring AbbVie's entire AndroGel patent estate invalid. The litigation was resolved through settlement and dismissal.

Could a generic company design around AndroGel patents?

Potentially. A generic applicant could pursue different excipients, delivery characteristics, dosing instructions, or label language. The result would depend on the specific claims and FDA-approved product.

Did the case determine when all generic testosterone gel could launch?

No. The case resolved the dispute between AbbVie and Mylan. It did not establish a universal launch date for every generic testosterone-gel manufacturer.

References

1. U.S. District Court for the District of Delaware. (2012). AbbVie Inc. v. Mylan Inc., No. 1:12-cv-00257. PACER docket records.

2. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.